Literature DB >> 28743134

Aneurysms of the Intracranial Segment of the Ophthalmic Artery Trunk: Case Report and Systematic Literature Review.

Simone Peschillo1, Francesco Biraschi2, Francesco Diana1, Claudio Colonnese1,3, Marco Marenco4, Roberto Delfini1.   

Abstract

Aneurysms arising from the ophthalmic artery trunk (OAT) are very rare, particularly in the artery's intracranial course. The onset of a subarachnoid hemorrhage (SAH) from a ruptured OAT aneurysm in this segment is extremely rare. We present a case and discuss the anatomy, clinical significance, and therapeutic options for an aneurysm at this site. We also retrospectively analyzed the record of a patient with a ruptured aneurysm of the intracranial segment of the OAT and conducted a comprehensive and systematic review of the PubMed and Scopus databases for literature on this pathology. Only one case report of SAH from an aneurysm of the intracranial segment of the OAT was published in the literature. Only in our case was the intracranial OAT segment aneurysm discovered in the acute phase of SAH. Conventional angiography with three-dimensional acquisition may help detect aneurysms at this level. Detailed knowledge of the anatomy of the OAT is of paramount importance for both surgical and endovascular approaches. Surgical treatment is complex because of difficulties in accessing the orbital region and the risk of optic nerve and vascular injuries. Endovascular treatment, when feasible, could be a good alternative to reduce the risk of loss of vision related to surgical manipulation. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2017        PMID: 28743134     DOI: 10.1055/s-0037-1604268

Source DB:  PubMed          Journal:  J Neurol Surg A Cent Eur Neurosurg        ISSN: 2193-6315            Impact factor:   1.268


  1 in total

1.  Partial medial clinoidectomy with optic canal roof drilling for clipping of ophthalmic artery aneurysms: how I do it.

Authors:  Adéla Bubeníková; Petr Skalický; Vladimír Beneš
Journal:  Acta Neurochir (Wien)       Date:  2022-09-15       Impact factor: 2.816

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.